BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30845115)

  • 1. Pediatric Langerhans cell histiocytosis: state of the science and future directions.
    Thacker NH; Abla O
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):122-131. PubMed ID: 30845115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
    Abla O; Weitzman S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in our understanding of genetic markers and targeted therapies for pediatric LCH.
    Bahabri A; Abla O
    Expert Rev Hematol; 2024 Jun; 17(6):223-231. PubMed ID: 38721670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
    Tran G; Huynh TN; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.
    Kobayashi M; Tojo A
    Cancer Sci; 2018 Dec; 109(12):3707-3713. PubMed ID: 30281871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Alterations in Langerhans Cell Histiocytosis.
    Rollins BJ
    Hematol Oncol Clin North Am; 2015 Oct; 29(5):839-51. PubMed ID: 26461146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.
    Aricò M
    Br J Haematol; 2016 Jun; 173(5):663-70. PubMed ID: 26913480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathophysiology and treatment of adult Langerhans cell histiocytosis].
    Tojo A; Kobayashi M
    Rinsho Ketsueki; 2020; 61(9):1028-1034. PubMed ID: 33162496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Langerhans cell histiocytosis.
    Rodriguez-Galindo C; Allen CE
    Blood; 2020 Apr; 135(16):1319-1331. PubMed ID: 32106306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?
    Berres ML; Merad M; Allen CE
    Br J Haematol; 2015 Apr; 169(1):3-13. PubMed ID: 25430560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adult Langerhans cell histiocytosis].
    de Menthon M; Meignin V; Mahr A; Tazi A
    Presse Med; 2017 Jan; 46(1):55-69. PubMed ID: 27816338
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.
    Egeler RM; Katewa S; Leenen PJ; Beverley P; Collin M; Ginhoux F; Arceci RJ; Rollins BJ;
    Pediatr Blood Cancer; 2016 Oct; 63(10):1704-12. PubMed ID: 27314817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.
    Li Q
    J Dermatolog Treat; 2023 Dec; 34(1):2279901. PubMed ID: 37941458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.
    Goyal G; Tazi A; Go RS; Rech KL; Picarsic JL; Vassallo R; Young JR; Cox CW; Van Laar J; Hermiston ML; Cao XX; Makras P; Kaltsas G; Haroche J; Collin M; McClain KL; Diamond EL; Girschikofsky M
    Blood; 2022 Apr; 139(17):2601-2621. PubMed ID: 35271698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.
    Murakami I; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Nagata K; Horie Y; Hayashi K; Imamura T; Morimoto A; Imashuku S; Gogusev J; Jaubert F; Takata K; Oka T; Yoshino T
    Cell Commun Signal; 2015 Feb; 13():13. PubMed ID: 25889448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications.
    Zinn DJ; Chakraborty R; Allen CE
    Oncology (Williston Park); 2016 Feb; 30(2):122-32, 139. PubMed ID: 26888790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.